Default Category
-
Grupo Velázquez
Mozo, Enrique; Gallo, Miguel ÁngelCase DG-1241StrategyEl fundador del grupo familiar Velázquez logró un extraordinario desarrollo de sus empresas a lo largo de casi treinta años. Pero su dedicación a los negocios fue en detrimento del tiempo y esfuerzo empleados en la educación de sus tres hijos. A la muerte del fundador, heredaron sus hijos y uno de ellos, Lorenzo, se hizo cargo de la dirección ejecutiva del grupo. Lorenzo continuó con cierto éxito los negocios familiares, al tiempo que llevaba un ...Starting at €8.20
-
Grupo Velázquez
Mozo, Enrique; Gallo, Miguel ÁngelCase DG-1241-EStrategyThe founder of the Velázquez family group achieved an extraordinary level of development for its companies over a period of almost 30 years. But his devotion to the businesses was in detriment to the time and effort spent on bringing up his three children. On the founder's death, his children inherited the group, and one of them, Lorenzo, took over its executive management. Lorenzo continued to manage the family business with a certain degree of...Starting at €8.20
-
Operation Warp Speed and the COVID-19 Vaccine
Schulman, Kevin; Thiagaraj, AbishekCase SGSB-SM345-EStrategyAs the COVID-19 pandemic shut down businesses and schools in 2020, global health authorities and governments kick-started the quest for a vaccine for the novel coronavirus. This case study details Operation Warp Speed, the $18 billion public-private partnership initiated by the U.S. government to accelerate the research, development, manufacture and distribution of COVID-19 vaccine therapies. The case explores the history of public-private partn...Starting at €8.20
-
The Teladoc and Livongo Merger
Schulman, Kevin; Surendra Jain, Adesh; Naude Bremer Du Plessis, PieterCase SGSB-SM349-EStrategyTeladoc and Livongo had ridden the tailwinds of the COVID-19 pandemic—and a merger between the two would offer a “one-stop-shop” for technology-driven care for patients with acute, chronic, and specialty care needs. The case study describes the regulatory history of telemedicine in the United States, and the licensing barriers that had inhibited virtual doctors’ visits—until the 2020 COVID-19 pandemic forced urgent changes to the ways doctors and...Starting at €8.20